Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
Benkert P, Maleska Maceski A, Schaedelin S, Oechtering J, Zadic A, Vilchez Gomez JF, Melie-Garcia L, Cagol A, Galbusera R, Subramaniam S, Lorscheider J, Galli E, Mueller J, Fischer-Barnicol B, Achtnichts L, Findling O, Lalive PH, Bridel C, Uginet M, Müller S, Pot C, Mathias A, Du Pasquier R, Salmen A, Hoepner R, Chan A, Disanto G, Zecca C, D'Souza M, Hemkens LG, Yaldizli Ö, Derfuss T, Roth P, Gobbi C, Brassat D, Tackenberg B, Pedotti R, Raposo C, Oksenberg J, Wiendl H, Berger K, Hermesdorf M, Piehl F, Conen D, Buser A, Kappos L, Khalil M, Granziera C, Abdelhak A, Leppert D, Willemse EAJ, Kuhle J; Swiss MS Cohort study (SMSC). Benkert P, et al. Among authors: brassat d. Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096. Online ahead of print. Ann Neurol. 2024. PMID: 39411917
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.
Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, Evdoshenko E, Thouvenot E, Trojano M, Norgren N, Teunissen C, Kappos L, Giovannoni G, Kuhle J; International Clinically Isolated Syndrome Study Group. Disanto G, et al. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9. doi: 10.1136/jnnp-2014-309690. Epub 2015 Feb 25. J Neurol Neurosurg Psychiatry. 2016. PMID: 25716934
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M, Munger KL, Martínez-Lapiscina EH, Barro C, Edan G, Freedman MS, Hartung HP, Montalbán X, Foley FW, Penner IK, Hemmer B, Fox EJ, Schippling S, Wicklein EM, Kappos L, Kuhle J, Ascherio A; BENEFIT Study Group. Cortese M, et al. Neurology. 2020 May 5;94(18):e1950-e1960. doi: 10.1212/WNL.0000000000009371. Epub 2020 Apr 16. Neurology. 2020. PMID: 32300060 Free PMC article. Clinical Trial.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators. Miller DH, et al. Neurology. 2015 Mar 17;84(11):1145-52. doi: 10.1212/WNL.0000000000001360. Epub 2015 Feb 13. Neurology. 2015. PMID: 25681448 Free PMC article. Clinical Trial.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Free article. Clinical Trial.
A benign form of neuromyelitis optica: does it exist?
Collongues N, Cabre P, Marignier R, Zéphir H, Papeix C, Audoin B, Lebrun-Frenay C, Pelletier J, Fontaine B, Vermersch P, Confavreux C, de Seze J; Group Members for NOMADMUS and CF-SEP. Collongues N, et al. Arch Neurol. 2011 Jul;68(7):918-24. doi: 10.1001/archneurol.2011.127. Arch Neurol. 2011. PMID: 21747032
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Gold R, et al. N Engl J Med. 2012 Sep 20;367(12):1098-107. doi: 10.1056/NEJMoa1114287. N Engl J Med. 2012. PMID: 22992073 Free article. Clinical Trial.
154 results